Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated Precied Office Description 23 FFB 2006.C. 371"

Approved for use through 3/31/2007. ONIR 0651-0021

Approved for use through 3/31	/2007. OMB 0651-0021						
บ.ั	S. PATENT AND TRADEMARK U.S. DEPARTMENT OF COM		ATTORNEY'S DOCKET NUMBER 21215YP				
	TTER TO THE UNITED ST	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)					
	ECTED OFFICE (DO/EO/ FILING UNDER 35 U.S.C.	10/569302					
	ON NO. INTERNATIONAL FILING	DATE	PRIORITY DATE CLAIMED				
PCT/US2004/028655	02 September 2004		10 September 2003				
TITLE OF INVENTION 17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS							
APPLICANT(S) FOR DO/EO/US	}						
Mildred L. Kaufman, Robert S	. Meissner, and Helen J. Mitchell		1				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:							
1. X This is a FIRST sub	mission of items concerning a filing	g under 35	U.S.C. 371.				
2. This is a SECOND of	or SUBSEQUENT submission of it	tems concer	ming a filing under 35 U.S.C. 371.				
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.							
4. X The US has been ele	ected (PCT Article 31).						
5. A copy of the Intern	A copy of the International Application as filed [35 U.S.C. 371(c)(2)]						
a. is attached hereto (required only if not communicated by the International Bureau).							
b. has been communicated by the International Bureau.							
c. X is not required, as the application was filed in the United States Receiving Office (RO/US).							
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].a. is attached hereto							
b. has been previously submitted under 35 U.S.C. 154(d)(4).							
	Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau).						
b. have been communicated by the International Bureau.							
c. have not been							
	d. X have not been made and will not be made.						
	An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].						
9. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].							
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].							
Items 11 to 20 below concern other document(s) or information included:							
	closure Statement under 37 CFR 1.9						
12. An assignment docu is included.	ment for recording. A separate cov	er sheet in	compliance with 37 CFR 3.28 and 3.31				
3. A preliminary amendment.							
14. An Application Data Sheet under 37 CFR 1.76.							
15. A substitute specification.							
16. A power of attorney and/or change of address letter.							
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.							
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).							
19. A second copy of the	English language translation of the	e internatio	nal application under 35 U.S.C.154(d)(4).				
20. Other items or information:							
	•						

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected of hee/Do/Eo/Us/Cohedning a Submission Under 20061"

Approved for use through 3/31/2007. OMB 0651-0021

U.S. APPLICATION N	•		R 1.5)	INTERN	IATIONAL APPLICATION NO.			ATTORNEY'S DOC	KET NUMBER
10/5	693	302	:	PCT/US	S2004/028655			21215YP	
The following fees are submitted:							CALCULATIONS	PTO USE ONLY	
21. A Basic national fee						\$300	\$300.00		
22. Examination fee (37 CFR 1.492(c))									
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)							\$0		
All other situations								\$200.00	
23. Search fee (37 CFR 1.492(b))								-	
If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)									
					onal application to the USPTO			£100.00	
					US and provided to the Office		\$100	\$100.00	
previously communic	ated to the	US by the	B	• • • • • • • • • • • • • • • • • • • •		•••••			
All other situations					TOTAL OF			\$600.00	
Additional fee for	or specifica	ation and di	awings file	ed in pap	er over 100 sheets (excluding			\$600.00	
	ım listing fi				The fee is \$250 for each addi				
Total Sheets	Extra Sh	neets			idditional 50 or fraction to a whole number)]	RATE		
- 100 =	0	/50	0	=	0	х	\$250.00	\$0.00	-
1			th or decla	ration la	ter than 30 months from the e	arliest o	claimed		
priority date [37 CF]	111	<u> .</u> NUMBER	EIL ED		NUMBER EVERA		DATE		
Total Claims		NUMBER		20	NUMBER EXTRA		RATE	#1.050.00	Γ
Independent Claims			41	- 20 =	21	X	\$50.00	\$1,050.00	
MULTIPLE DEPENI	DENT CLA	A IM(C) (if	l Annliachla)	- 3 =	0	+	\$200.00	\$0.00	
MOLTIFLE DEFENI					AMIONG (OUDTOTALL)		\$360.00	\$1.650.00	
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) =						\$1,650.00	<u> </u>		
Processing fee of \$130 claimed priority date (-	English tr	anslation	later than 30 months from the	e earlie	st +		
TOTAL NATIONAL FEE =							\$1,650.00		
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.									
TOTAL FEES ENCLOSED =						=	\$1,650.00		
								Amount to be	
								refunded:	
								Amount to be charged:	
a. A check in the amount of \$ to cover the above fees is enclosed.									
b. Please charge my Deposit Account No. 13-2755 in the amount of \$1,650.00 to cover the above fees.									
A duplicate copy of this sheet is enclosed. c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any									
overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:									
Customer No. 000210									
MERCK & CO., INC.									
Patent Department, RY60-30						سنند ۵	. Shatynohi		
P.O. Box 2000 SIGNATURE 126 East Lincoln Avenue						URE	9.		
Rahway, New Je					D ,		Chat1		
						ricia A AME	. Shatynski		
DATE: February 23, 2006									
PHONE #: (/32) 394-1032					43,109 REGISTRATION NUMBER				
					IXL		• - • • • • • • •		

IAP12 Rec'd PCT/TTO 23 FEB 2006

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:	21215YP
International Appln No.:	PCT/US2004/028655
International Filing Date:	02 September 2004
Priority Date:	10 September 2003
Title:	17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
Inventors:	Mildred L. Kaufman, Robert S. Meissner, and Helen J. Mitchell

21215YP

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT February 23, 2006

EXPRESS MAIL NO. EV 660602211 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O./BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY